Treatment of Chronic Myelogenous Leukemia in Blast Crisis and- in Accelerated Phase with High- or Intermediate-dose Cytosine Arabinoside and Amsacrine

References

• Herzig R. H., Phillips G. L., Lazarus H. M., Wolff S. N., Herzig G. P. High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treatment Reports 1985; 69: 881–883
   PubMedGoogle Scholar
• Iacoboni S. J., Plunkett W., Kantarjian H. M., Estey E., Keating M. J., McCredie K. B., Freireich E. J. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic nyelogenous leukemia in blast crisis. Journal of Clinical Oncology 1986; 4: 1079–1088
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Talpaz M., Waiters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. American Journal of Medicine 1987; 83: 445–454
   PubMed Web of Science ®Google Scholar
• Zittoun R., Bury J., Stryckmans P., Lowenberg B., Peetermans M., Rozendaal K. V., Haanen C., Kerkhofs M., Jehn U., Willemze R. Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treatmenr Reports 1985; 69: 1447–1448
   PubMedGoogle Scholar
• Marie J. P., Zittoun R. Chemotherapy of acute myelogenous leukemia. Chemotherapy of Blood Malignant Diseases, R. Zittoun. Baillere Tindall (London), 4, 1991; 97–112
   Google Scholar
• Sokal J. E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Seminars in Hematology 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Coleman M., Silver R. T., Pajak T. F., Cavalli F., Rai K. R., Kostinas J. E., Glidewell O., Holland J. F. Combination chemotherapy for terminal phase of chronic myelocytic leukemia. Blood 1980; 55: 29–36
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Walters R. S., Keating M. J., Talpaz M., Anderson B., Breau M., McCredie K. B., Freireich E. J. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 1988; 62: 672–676
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Leong S. S., Gomez G. A. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocyte leukemia. Cancer 1987; 59: 197–202
   PubMed Web of Science ®Google Scholar
• Pommier Y., Pochat L., Marie J. P., Zittoun R. High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics. Cancer Treatmenr Reports 1983; 67: 371–373
   PubMedGoogle Scholar
• Kuwazuru Y., Yoshimura A., Hanada S., Ichikawa M., Saito T., Vozumi K. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia in blast crisis. British Journal of Haemarology 1990; 74: 2429
   Google Scholar
• Marie J. P., Legrand O., Russo D., Zhou D. C., Suberville A. M., Zittoun R. Multidrug resistance (MDR) gene exuression in acute non lymphoblastic. leukemia: sequential analysis. Leukemia and Lymphoma 1992, (in press).
   PubMedGoogle Scholar
• Zittoun R. m-AMSA: a review of clinical data. European Journal of Cancer and Clinical Oncology 1985; 21: 649–653
   PubMedGoogle Scholar
• Legha S. S., Keating M. J., McCredie K. B., Bodey G. P., Freireich E. J. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood 1982; 60: 484490
   Google Scholar
• Lawrence H. J., Ries C. A., Reynolds R. D., Lewis J. P., Koretz M. M., Torti F. M. AMSA- promising new agent in refractory acute leukemia. Cancer Treatment Reports 1982; 66: 1475–1478
   PubMedGoogle Scholar
• Plunkett W., Liliemark J., Adams T. M., Nowak B., Estey E., Kantarjian H., Keating M. J. Saturation of 1-b-D-arabinofuranosylcytosine 5prime;-triphosphate accumulation in leukemia cells during high-dose I-b-D-arabinofuranosyIcytosine therapy. Cancer Research 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Cervantes F., Rozman M., Rosell J., Urbano-Lspizua A., Montserrat E., Rozman C. A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. British Journal of Haematology 1990; 76: 27–32
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., Kurzrock R., Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Seminars in Hematology 1988; 25: 62–73
   PubMed Web of Science ®Google Scholar
• Foley H. T., Bennet J. M., Carbone P. P. Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Archives of Internal Medicine 1969; 123: 166–170
   PubMed Web of Science ®Google Scholar
• Canellos G. P., De Vita W. T., Whang Peng J. Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood 1971; 38: 671–679
   PubMed Web of Science ®Google Scholar
• Vallejos C. S., Trujillo J. M., Cork A., Bodey G. P., McCredie K. B., Freireich E. J. Blastic crisis in chronic granulocytic leukemia: experience in 39 patients. Cancer 1974; 34: 1806–1812
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Worm A. M., Hainau B. Blastic transformation of chronic myelocytic leukemia: clinical manifestations, prognostic factors and results of therapy. Scandinavian Journal of Haematology 1977; 18: 292–300
   PubMedGoogle Scholar
• Hayes D. M., Ellison R. R., Glidewell O. Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer Chemotherapy Reports 1974; 58: 233–247
   Google Scholar
• Spiers A. S. D., Goldman J. M., Catovsky D., Costello C., Buskard N. A., Galton A. G. Multiple drug chemotherapy for acute leukemia. The TRAMPCOL regimen: results in 86 patients. Cancer 1977; 40: 40–49
   Web of Science ®Google Scholar
• Walters R. S., Kantarjian H. M., Keating M. J., Talpaz M., Childs C. C., McCredie K. B., Freireich E. J. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusion plus high-dose decadron. Cancer 1988; 60: 1708–1712
   Web of Science ®Google Scholar
• Koller C. A., Miller D. M. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. The New England Journal of Medicine 1986; 315: 1433–1438
   PubMed Web of Science ®Google Scholar